title: Nanomedicine based nanoparticles for neurological disorders.
abstract: Human health is severely hampered by a majority of the neurological disorders such as the brain tumors, degenerative Alzheimer's disease, Parkinson's disease and those involving inflammatory component. Owing to the stringent protection offered by the blood brain barrier, conventional therapeutics gain limited access and therefore, are therapeutically suboptimal. Hence, research has now focused to develop the novel drug delivery systems with a prime motto of maintaining therapeutic drug levels inside the brain, avoiding non-specific tissue distribution. The introduction of nanotechnology has addressed few of these objectives and opened up new avenues for even more improvization. To some extent, nanodelivery systems were successful in crossing the blood brain barrier and accessing the remote areas of the brain. They also have shown tremendous potential in delivering the therapeutic and diagnostic aids following systemic administration. What revolutionised the nano applications is the development of "smart" nanosystems, whose surface is tailor made for the effective theranostic delivery. However, a detailed understanding of the long term nanoformulation toxicities, along with the neuropathology, is the critical future question to be addressed. In this review, a brief introduction of the prominent neurological disorders and detailed applications of nanotechnology are discussed.
authors.forename: Bhasker
authors.initials: B
authors.lastname: Sriramoju
authors.forename: Rupinder K
authors.initials: RK
authors.lastname: Kanwar
authors.affiliation: Nanomedicine- Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), School of Medicine, Faculty of Health, Deakin University, Waurn Ponds, Victoria 3217, Australia. jagat.kanwar@deakin.edu.au.
authors.forename: Jagat R
authors.initials: JR
authors.lastname: Kanwar
mesh_terms: D001812:Blood-Brain Barrier / Q000378:metabolism; D004337:Drug Carriers / Q000737:chemistry; D006801:Humans; D050997:Nanomedicine; D053758:Nanoparticles / Q000737:chemistry*; D009422:Nervous System Diseases / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000737:chemistry; D011108:Polymers / Q000737:chemistry
chemical_list: D004337:Drug Carriers; D018696:Neuroprotective Agents; D011108:Polymers